obicetrapib
Jump to navigation
Jump to search
Indications
Dosage
Adverse effects
- none noted
Mechanism of action
- selective CETP inhibitor
- lowers LDL cholesterol, Lp(a) cholesterol
- increases HDL cholesterol
References
- ↑ Lou N Oral Obicetrapib Takes Lipid Lowering to Another Level in Trials. CETP inhibitor tied to substantial improvements in LDL, HDL, apoB, Lp(a). MedPage Today May 7, 2025 https://www.medpagetoday.com/cardiology/dyslipidemia/115468
Nicholls SJ, Nelson AJ, Ditmarsch M; BROADWAY Investigators. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025 May 7. PMID: https://pubmed.ncbi.nlm.nih.gov/40337982 https://www.nejm.org/doi/full/10.1056/NEJMoa2415820
Sarraju A, Brennan D, Hayden K et al Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. 2025. May 7 Not yet indexed in PubMed https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00721-4/abstract - ↑ Emara A, Gadelmawla AF, Awashra A, et al. Obicetrapib for dyslipidemia with or without cardiovascular risk: A GRADE-assessed meta-analysis of randomized trials with trial sequential evidence. Diabetes Obes Metab. 2025 Nov 25 PMID: https://pubmed.ncbi.nlm.nih.gov/41287560